Katelin A Mirkin1, Christopher S Hollenbeak1,2, Joyce Wong3. 1. Department of Surgery, Division of Surgical Oncology, The Pennsylvania State University, College of Medicine, 500 University Drive, MC H070, Hershey, PA, 17033, USA. 2. Department of Public Health Sciences, The Pennsylvania State University, College of Medicine, Hershey, PA, USA. 3. Department of Surgery, Division of Surgical Oncology, The Pennsylvania State University, College of Medicine, 500 University Drive, MC H070, Hershey, PA, 17033, USA. joyce.wong02@gmail.com.
Abstract
BACKGROUND: Longer time to surgery is associated with worse outcomes in several cancers. We sought to identify disparities in time from diagnosis to surgery in pancreatic cancer and whether delays to surgery correlated with worse survival. METHODS: The US National Cancer Database (2003-2011) was reviewed for patients with clinical stages I-II pancreatic adenocarcinoma who underwent surgical resection. Patients who received neoadjuvant therapy were excluded. Linear regression, Kaplan-Meier analyses, and Cox regression were performed as 3-month landmark analyses. RESULTS: Of the 14,807 patients included, 37.8% underwent resection ≤ 1 week, 13.7% 1-2 weeks, 25.4% 2-4 weeks, 19.5% 4-8 weeks, and 3.7% 8-12 weeks. Older age, Medicare coverage, greater distance from hospital, treatment at an academic center, and greater comorbidities were associated with increased time. After excluding patients treated within 1 week of diagnosis and controlling for patient, disease, and treatment characteristics, greater time was not associated with worse survival (2-4, HR 1.03, P = 0.399; 4-8, HR 0.98, P = 0.529; 8-12, P = 0.123). CONCLUSIONS: For patients with stages I-II pancreatic adenocarcinoma, there are disparities in surgical wait times. However, earlier initiation of surgical resection within 12 weeks of diagnosis is not associated with a survival benefit. This suggests that allowing time for confirmatory testing and optimization in preparation for surgery may not negatively impact survival.
BACKGROUND: Longer time to surgery is associated with worse outcomes in several cancers. We sought to identify disparities in time from diagnosis to surgery in pancreatic cancer and whether delays to surgery correlated with worse survival. METHODS: The US National Cancer Database (2003-2011) was reviewed for patients with clinical stages I-II pancreatic adenocarcinoma who underwent surgical resection. Patients who received neoadjuvant therapy were excluded. Linear regression, Kaplan-Meier analyses, and Cox regression were performed as 3-month landmark analyses. RESULTS: Of the 14,807 patients included, 37.8% underwent resection ≤ 1 week, 13.7% 1-2 weeks, 25.4% 2-4 weeks, 19.5% 4-8 weeks, and 3.7% 8-12 weeks. Older age, Medicare coverage, greater distance from hospital, treatment at an academic center, and greater comorbidities were associated with increased time. After excluding patients treated within 1 week of diagnosis and controlling for patient, disease, and treatment characteristics, greater time was not associated with worse survival (2-4, HR 1.03, P = 0.399; 4-8, HR 0.98, P = 0.529; 8-12, P = 0.123). CONCLUSIONS: For patients with stages I-II pancreatic adenocarcinoma, there are disparities in surgical wait times. However, earlier initiation of surgical resection within 12 weeks of diagnosis is not associated with a survival benefit. This suggests that allowing time for confirmatory testing and optimization in preparation for surgery may not negatively impact survival.
Entities:
Keywords:
Delay in treatment; Disparities; NCDB; Pancreatic cancer; Time to surgery; Wait time
Authors: Praful Ravi; Akshay Sood; Marianne Schmid; Firas Abdollah; Jesse D Sammon; Maxine Sun; Dane E Klett; Briony Varda; James O Peabody; Mani Menon; Adam S Kibel; Paul L Nguyen; Quoc-Dien Trinh Journal: Ann Surg Date: 2015-12 Impact factor: 12.969
Authors: Spencer R McLean; Divya Karsanji; Jennifer Wilson; Elijah Dixon; Francis R Sutherland; Janice Pasieka; Chad Ball; Oliver F Bathe Journal: J Surg Oncol Date: 2013-04-26 Impact factor: 3.454
Authors: William G Paterson; William T Depew; Pierre Paré; Denis Petrunia; Connie Switzer; Sander J Veldhuyzen van Zanten; Sandra Daniels Journal: Can J Gastroenterol Date: 2006-06 Impact factor: 3.522
Authors: Melissa M Murphy; Jessica P Simons; Joshua S Hill; Theodore P McDade; Sing Chau Ng; Giles F Whalen; Shimul A Shah; Lynn H Harrison; Jennifer F Tseng Journal: Cancer Date: 2009-09-01 Impact factor: 6.860
Authors: Valérie Jooste; Olivier Dejardin; Véronique Bouvier; Patrick Arveux; Marc Maynadie; Guy Launoy; Anne-Marie Bouvier Journal: Int J Cancer Date: 2016-05-14 Impact factor: 7.396
Authors: Scott C Fligor; Sophie Wang; Benjamin G Allar; Savas T Tsikis; Ana Sofia Ore; Ashlyn E Whitlock; Rodrigo Calvillo-Ortiz; Kevin R Arndt; Sidhu P Gangadharan; Mark P Callery Journal: J Gastrointest Surg Date: 2020-06-30 Impact factor: 3.452
Authors: Anne Jacobsen; Mirianna Hobbs; Susanne Merkel; Anke Mittelstädt; Franziska Czubayko; Christian Krautz; Georg F Weber; Robert Grützmann; Maximilian Brunner Journal: J Clin Med Date: 2022-07-29 Impact factor: 4.964
Authors: J-J Tuech; A Gangloff; F Di Fiore; P Michel; C Brigand; K Slim; M Pocard; L Schwarz Journal: J Visc Surg Date: 2020-03-31 Impact factor: 2.043
Authors: R Casolino; C Braconi; G Malleo; S Paiella; C Bassi; M Milella; S B Dreyer; F E M Froeling; D K Chang; A V Biankin; T Golan Journal: Ann Oncol Date: 2020-11-26 Impact factor: 32.976
Authors: M Brugel; O Bouché; R Kianmanesh; L Teuma; A Tashkandi; J M Regimbeau; P Pessaux; B Royer; R Rhaiem; C Perrenot; C Neuzillet; T Piardi; S Deguelte Journal: BMC Surg Date: 2021-12-07 Impact factor: 2.102
Authors: Denise Garcia; Julie B Siegel; David A Mahvi; Biqi Zhang; David M Mahvi; E Ramsay Camp; Whitney Graybill; Stephen J Savage; Antonio Giordano; Sara Giordano; Denise Carneiro-Pla; Mahsa Javid; Aaron P Lesher; Andrea Abbott; Nancy Klauber DeMore Journal: Clin Oncol Res Date: 2020-06-26